BPG is committed to discovery and dissemination of knowledge
Featured Articles
4/15/2026 8:59:02 AM | Browse: 107 | Download: 319
 |
Received |
|
2026-01-20 02:22 |
|
Peer-Review Started |
|
2026-01-20 02:23 |
|
First Decision by Editorial Office Director |
|
2026-01-27 07:32 |
|
Return for Revision |
|
2026-01-27 07:32 |
|
Revised |
|
2026-02-03 00:35 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-06 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-06 05:43 |
|
Articles in Press |
|
2026-03-06 05:43 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-07 00:48 |
|
Publish the Manuscript Online |
|
2026-04-15 07:40 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© Author(s) (or their employer(s)) 2026. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Olanzapine-based vs neurokinin-1 receptor antagonist antiemetic regimens in highly emetogenic chemotherapy: Systematic review and meta-analysis of efficacy and safety
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Advaitha Mv, Nikhilesh Anand, Biacin Babu, Ayoola Awosika, Uttam Udayan, Jacqueline Mendoza, Alissa Lopez, Brahmaiahchari Rangachari, Sabyasachi Maity and Bharathi S Gadad |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ayoola Awosika, MD, Department of Family and Community Medicine, University of Illinois College of Medicine Peoria, 1 Illini Drive, Bloomington, IL 61601, United States. ayoolaawosika@yahoo.com |
| Key Words |
Carboplatin; Cisplatin; Highly emetogenic chemotherapy; Neurokinin-1 antagonist; Olanzapine |
| Core Tip |
Chemotherapy-induced nausea and vomiting commonly occur in patients receiving highly emetogenic chemotherapy, with rates over 90% without prophylaxis. Effective prevention preserves quality of life, supports treatment adherence, and reduces healthcare use. This study demonstrated that olanzapine-based regimens effectively prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, with pronounced control of delayed-phase nausea. Low dose provides predictable efficacy, manageable sedation, oral convenience, and cost-effectiveness. Clinically, olanzapine should be included in first-line antiemetic protocols to improve patient comfort, reduce the need for rescue medication, and support adherence to treatment. |
| Publish Date |
2026-04-15 07:40 |
| Citation |
Mv A, Anand N, Babu B, Awosika A, Udayan U, Mendoza J, Lopez A, Rangachari B, Maity S, Gadad BS. Olanzapine-based vs neurokinin-1 receptor antagonist antiemetic regimens in highly emetogenic chemotherapy: Systematic review and meta-analysis of efficacy and safety. World J Clin Cases 2026; 14(12): 119112
|
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i12/119112.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i12.119112 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
